59 related articles for article (PubMed ID: 17400332)
1. Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients.
Matakidou A; El Galta R; Webb EL; Rudd MF; Bridle H; Eisen T; Houlston RS;
Lung Cancer; 2007 Aug; 57(2):207-12. PubMed ID: 17400332
[TBL] [Abstract][Full Text] [Related]
2. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population.
Sreeja L; Syamala V; Raveendran PB; Santhi S; Madhavan J; Ankathil R
Cancer Invest; 2008 Feb; 26(1):41-6. PubMed ID: 18181044
[TBL] [Abstract][Full Text] [Related]
3. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
Matakidou A; El Galta R; Rudd MF; Webb EL; Bridle H; Eisen T; Houlston RS
Br J Cancer; 2007 Jun; 96(12):1904-7. PubMed ID: 17519899
[TBL] [Abstract][Full Text] [Related]
4. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
5. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
7. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
9. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression.
De Feo E; Persiani R; La Greca A; Amore R; Arzani D; Rausei S; D'Ugo D; Magistrelli P; van Duijn CM; Ricciardi G; Boccia S
Mutat Res; 2009 Apr; 675(1-2):60-5. PubMed ID: 19386249
[TBL] [Abstract][Full Text] [Related]
10. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.
Masago K; Fujita S; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Ichikawa M; Mio T; Mishima M
Cancer Sci; 2009 Oct; 100(10):1917-22. PubMed ID: 19594543
[TBL] [Abstract][Full Text] [Related]
11. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia.
Kochethu G; Delgado J; Pepper C; Starczynski J; Hooper L; Krishnan S; Fegan C; Pratt G
Leuk Res; 2006 Sep; 30(9):1113-8. PubMed ID: 16458962
[TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
13. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
Heist RS; Zhai R; Liu G; Zhou W; Lin X; Su L; Asomaning K; Lynch TJ; Wain JC; Christiani DC
J Clin Oncol; 2008 Feb; 26(6):856-62. PubMed ID: 18281657
[TBL] [Abstract][Full Text] [Related]
14. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
Rajkumar T; Samson M; Rama R; Sridevi V; Mahji U; Swaminathan R; Nancy NK
Breast Cancer Res Treat; 2008 Nov; 112(1):81-7. PubMed ID: 18058229
[TBL] [Abstract][Full Text] [Related]
15. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
[TBL] [Abstract][Full Text] [Related]
16. Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.
Kumari A; Bahl C; Singh N; Behera D; Sharma S
Mol Biol Rep; 2016 Dec; 43(12):1383-1394. PubMed ID: 27614750
[TBL] [Abstract][Full Text] [Related]
17. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Fontanini G
Oncol Rep; 2008 Mar; 19(3):771-3. PubMed ID: 18288414
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphism in esophageal cancer related gene 1: an analysis in resected oral squamous cell carcinoma patients.
Blessmann M; Pohlenz P; Atac A; Kaifi JT; Eulenburg C; Kalinin V; Merkert P; Smeets R; Heiland M; Blake F; Schmelzle R; Izbicki JR
Int J Oral Maxillofac Surg; 2009 Jul; 38(7):779-84. PubMed ID: 19394797
[TBL] [Abstract][Full Text] [Related]
20. p53 codon 72 polymorphism and HPV status in lung cancer.
Buyru N; Altinisik J; Isin M; Dalay N
Med Sci Monit; 2008 Sep; 14(9):CR493-7. PubMed ID: 18758421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
